
De-risking prostate cancer screening with ClarityDX Prostate
ClarityDX Prostate builds upon the utility of clinical features and blood-based biomarkers to determine a patient’s risk of having aggressive prostate cancer. This empowers patients and their healthcare providers make more informed healthcare decisions.

Dr. John Lewis
CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta
Recent news
Thin Air Labs Founder Mindset Podcast with Catalina Vasquez
Click here for the Season 3 Episode 8 podcast In this [...]
Alberta Health Innovation Passport: ClarityDX Prostate reduces unnecessary biopsies and improves patient outcomes
HealthPro Canada Alberta Health Innovation Passport - Nanostics Dr. Desmond [...]
Edmonton Global Trade Heroes Series – Nanostics’ ClarityDX Prostate early diagnostic test for aggressive prostate cancer
Nanostics Clinical Laboratory. Photo credit: Adam Becker, Intercept [...]
2024 Prostate cancer screening update
Our success is possible thanks to the support of our many Canadian and international collaborators, funders, and partners.




















